China Unconditionally Approves Hangyang-Shandong Haili Chemical JV and Shanghai Pharma Acquisition of 18 Firms
China's State Administration for Market Regulation unconditionally approved two deals between July 13 and July 19, 2026: a new joint venture between Hangyang Group Co. , Ltd. and Shandong Haili Chemical Co. , and the acquisition of equity in 18 companies, including Shanghai Pharma Yiyi Pharmacy (Huimin) Co. , by Shanghai Pharma Big Health Cloud Business Co.
- Effective
- +9
- Intensity
- 30
- Confidence
- 80%
- Horizon
- Short term